Volastra Therapeutics
Volastra Therapeutics's Overview
Volastra Therapeutics is a clinical-stage biotechnology company based in New York, dedicated to transforming cancer treatment by targeting chromosomal instability (CIN), a hallmark of many aggressive cancers. Leveraging their proprietary CINtech platform, Volastra identifies and validates novel CIN-related targets and develops first-in-class therapeutics. Their lead programs aim to exploit the unique vulnerabilities of CIN-high tumors, offering potential new hope for patients with difficult-to-treat cancers. The company was co-founded by leading cancer biologists and is backed by a syndicate of top-tier life science investors.
Where is Volastra Therapeutics's Headquarters?
HQ Function
Serves as the central hub for research and development, clinical operations, and corporate administration.
Notable Features:
Located in the Alexandria Center for Life Science, a state-of-the-art biotech campus offering advanced laboratory facilities and fostering collaboration within the NYC life sciences ecosystem.
Work Culture:
Likely a dynamic, innovative, and science-driven environment, characteristic of a cutting-edge biotech firm. Emphasis on collaboration, scientific rigor, and a mission-driven approach to tackling cancer.
HQ Significance:
Strategic location in a major U.S. biotech hub provides access to world-class talent, research institutions, and investment opportunities, accelerating drug discovery and development.
Values Reflected in HQ: Innovation, scientific excellence, collaboration, and a patient-centric approach to developing transformative cancer therapies.
Location:
While Volastra Therapeutics's primary physical operations are based in its New York City headquarters, its global reach is extended through international clinical trial sites for its drug candidates, collaborations with research institutions worldwide, and engagement with the global investment community. Specific countries for clinical trials may vary depending on the phase and requirements of their development programs.
Street Address:
450 East 29th Street, Floor 10
City:
New York
State/Province:
NY
Country:
USA
Volastra Therapeutics's Global Presence
Buying Intent Signals for Volastra Therapeutics
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Volastra Therapeutics
As of April 2025, Volastra Therapeutics' leadership includes:
Investors of Volastra Therapeutics
Volastra Therapeutics has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Volastra Therapeutics has actively strengthened its leadership team over the past year, notably with appointments to Chief Medical Officer and Chief Financial and Business Officer roles, signaling a period of growth and advancement in its clinical programs.
New Appointments:
Technology (Tech Stack) used by Volastra Therapeutics
Discover the tools Volastra Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Volastra Therapeutics Email Formats and Examples
Common email formats for companies like Volastra Therapeutics often use a combination of first name, last name, or initials. While not officially published, a likely format is [first_initial][last]@[companydomain].com or [first].[last]@[companydomain].com. For specific inquiries, it is always best to use official contact channels provided on their website.
[first_initial][last]@volastra.com
Format
jdoe@volastra.com
Example
70%
Success rate
News and media
Volastra Therapeutics Press Release • May 8, 2024
Volastra Therapeutics Announces Oral Presentation of Promising Preclinical Data on its KIF18A Inhibitor, Sovilnesib (VLS-1488), at the 2024 ASCO Annual Meeting
Volastra announced an upcoming oral presentation at the 2024 ASCO Annual Meeting detailing preclinical data for sovilnesib (VLS-1488), its KIF18A inhibitor. The data highlights its potential in chromosomally unstable (CIN) high solid tumors, including ovarian and triple-negative breast cancer models....more
PR Newswire • October 26, 2023
Volastra Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of VLS-1488, a KIF18A Inhibitor, for Solid Tumors
Volastra Therapeutics announced that the first patient has been dosed in its Phase 1 clinical trial evaluating VLS-1488 (sovilnesib), a first-in-class KIF18A inhibitor, in patients with solid tumors characterized by high levels of chromosomal instability....more
Volastra Therapeutics Press Release • July 12, 2023
Volastra Therapeutics Appoints Rachel N. K. Zolot Schwartz as Chief Financial and Business Officer
Volastra Therapeutics announced the appointment of Rachel N. K. Zolot Schwartz as its Chief Financial and Business Officer. Ms. Zolot Schwartz brings extensive experience in biotech finance, corporate strategy, and business development....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Volastra Therapeutics, are just a search away.